Sulopenem Versus Ertapenem for Complicated Intra-abdominal Infection (cIAI)
Status:
Completed
Trial end date:
2019-10-02
Target enrollment:
Participant gender:
Summary
This is a prospective, Phase 3, randomized, multi-center, double-blind study of the efficacy,
tolerability and safety of sulopenem followed by sulopenem-etzadroxil/probenecid versus
ertapenem followed by ciprofloxacin-metronidazole for treatment of complicated
intra-abdominal infections in adults.
Phase:
Phase 3
Details
Lead Sponsor:
Iterum Therapeutics, International Limited Iterum Therapeutics, US Limited